Core Viewpoint - Eton Bio (06998) shares rose nearly 9% at the close, currently up 6.88% at HKD 2.95, with a trading volume of HKD 3.5091 million following the announcement of the completion of the first dosing in a Phase II clinical trial for the new drug EDP167 targeting homozygous familial hypercholesterolemia (HoFH) [1] Group 1 - Eton Bio announced that the Phase II clinical trial for EDP167 has commenced, focusing on adult patients with homozygous familial hypercholesterolemia [1] - The primary endpoint of the trial is the change in LDL-C levels from baseline after 24 weeks of treatment, with results expected by Q4 2026 [1] - The company underwent a reverse merger with Jiahe Biotechnology, marking the official establishment of Eton Bio and a new phase in strategic integration and development [1] Group 2 - The Chinese stock name for Jiahe Biotechnology has been changed from "Jiahe Biotechnology" to "Eton Bio," effective from 9:00 AM on February 6, 2026 [1]

Group 1 - The core point of the article is that Eton Pharma (06998) experienced a nearly 9% increase in stock price, currently trading at 2.95 HKD, with a trading volume of 3.5091 million HKD following the announcement of the completion of the first dosing in a Phase II clinical trial for the new drug EDP167 [1] - EDP167 is being tested in a multicenter, dose-exploration, open-label trial targeting adult patients with homozygous familial hypercholesterolemia (HoFH), with the primary endpoint being the change in LDL-C levels from baseline after 24 weeks of treatment, expected to complete the primary endpoint assessment by Q4 2026 [1] - On December 30, Eton Pharma completed a reverse acquisition with Jiahe Biotech, marking the official establishment of Eton Pharma and entering a new phase in strategic integration and development, with the Chinese stock name changing from "Jiahe Biotech" to "Eton Pharma" effective February 6, 2026 [1]

Core Viewpoint - Eton Pharma (06998) announced the successful completion of the first dosing of the EDP167 Phase II clinical trial for patients with homozygous familial hypercholesterolemia (HoFH) [1] Group 1: Clinical Trial Details - The EDP167 Phase II clinical trial is a multicenter, dose-exploration, open-label study aimed at evaluating the efficacy and safety of EDP167 in adult patients with HoFH [1] - The primary endpoint of the trial is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline after 24 weeks of the first dosing [1] - The evaluation of the primary endpoint is expected to be completed by the fourth quarter of 2026 [1]

Core Viewpoint - Eton Pharma (06998) announced the successful completion of the first dosing of its small nucleic acid innovative drug EDP167 in a Phase II clinical trial targeting adult patients with homozygous familial hypercholesterolemia (HoFH) [1] Group 1: Clinical Trial Details - The Phase II clinical trial for EDP167 is a multicenter, dose-exploration, open-label study [1] - The trial aims to evaluate the efficacy and safety of EDP167 in HoFH patients [1] - The primary endpoint is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline after 24 weeks of the first dosing [1] Group 2: Timeline - The evaluation of the primary endpoint is expected to be completed by the fourth quarter of 2026 [1]

Core Viewpoint - Eton Pharma (06998.HK) has successfully completed the first dosing of a subject in the Phase II clinical trial for its small nucleic acid innovative drug EDP167, targeting adult patients with homozygous familial hypercholesterolemia (HoFH) [1] Group 1 - The Phase II clinical trial for EDP167 is a multi-center, dose-exploration, open-label study [1] - The trial aims to evaluate the efficacy and safety of EDP167 in HoFH patients [1] - The primary endpoint is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline after 24 weeks of the first dosing [1] Group 2 - The primary endpoint assessment is expected to be completed by the fourth quarter of 2026 [1]